Stifel lowered the firm’s price target on SLB (SLB) to $60 from $62 and keeps a Buy rating on the shares. Though international growth rates are slowing, the firm says Q3 results, Q4 guidance, and the 2025 outlook support its belief that the risk/reward in the shares remains favorable and that SLB is well positioned to deliver solid growth and robust free cash flow over the next few years.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLB:
- SLB price target lowered to $61 from $63 at Barclays
- SLB price target lowered to $62 from $74 at Evercore ISI
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- SLB Earnings: SLB’s Q3 Earnings Rise amid Cautious Market Conditions
- Morning Movers: CVS Health sinks following CEO change, weak guidance